Biomarin Pharmaceutical Stock Target Price and Analyst Consensus
| BMRN Stock | USD 69.44 1.16 1.64% |
The current analyst and expert consensus on Biomarin Pharmaceutical is Strong Buy with 7 buy recommendations. The current projected Biomarin Pharmaceutical target price consensus is 97.66, with 26 analyst opinions. Biomarin Pharmaceutical buy-or-sell recommendation module provides average expert sentiment on the projected Biomarin Pharmaceutical target price to derive its highest and lowest estimates based on target price estimated volatility of 1.7066. Check out Macroaxis Advice on Biomarin Pharmaceutical to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
Lowest Forecast 88.87 | Highest Forecast 108.41 | Target Price 97.66 |
Biomarin |
It's important to approach Biomarin Pharmaceutical's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Biomarin Pharmaceutical Target Price Consensus
Biomarin target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Biomarin Pharmaceutical's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 26 | Strong Buy |
Most Biomarin analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Biomarin stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Biomarin Pharmaceutical, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBiomarin Pharmaceutical Target Price Projection
Biomarin Pharmaceutical's current and average target prices are 69.44 and 97.66, respectively. The current price of Biomarin Pharmaceutical is the price at which Biomarin Pharmaceutical is currently trading. On the other hand, Biomarin Pharmaceutical's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Biomarin Pharmaceutical Market Quote on 15th of March 2025
Target Price
Analyst Consensus On Biomarin Pharmaceutical Target Price
Biomarin Pharmaceutical Analyst Ratings
Biomarin Pharmaceutical's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Biomarin Pharmaceutical stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Biomarin Pharmaceutical's financials, market performance, and future outlook by experienced professionals. Biomarin Pharmaceutical's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Biomarin Pharmaceutical price targets
Biomarin Pharmaceutical's stock target price is an estimate of its future price, usually made by analysts. Using Biomarin Pharmaceutical's target price to determine if it is a suitable investment can be done through the following steps:- Look at Biomarin Pharmaceutical's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Biomarin Pharmaceutical's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Biomarin Pharmaceutical Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Biomarin Pharmaceutical is a key component of Biomarin Pharmaceutical valuation and have some predictive power on the future returns of a Biomarin Pharmaceutical.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested few shares | |
 | Macroaxis Picks Invested few shares | |
 | ESG Investing Invested few shares | |
 | SRI Sustainable Growth Invested few shares | |
 | Business Services Invested few shares | |
 | Driverless Cars Invested over 60 shares | |
 | Apparel Invested over 40 shares | |
 | Casinos Sold over 90 shares | |
 | Utilities Invested over 90 shares | |
Check out Macroaxis Advice on Biomarin Pharmaceutical to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.